新闻

Verona Pharma plc (Nasdaq: VRNA) announces its development partner, Nuance Pharma, has dosed the first subject in its ENHANCE - China Phase 3 trial for the maintenance treatment of COPD

Nuance Pharma announces dosing of first patient in the ENHANCE - China Phase III Trial for the maintenance treatment of chronic obstructive pulmonary disease ("COPD") of its novel

优锐医药亚太区域首款商业产品，Bentrio™鼻喷剂已在中国香港首发上市！

Altamira Therapeutics Ltd. reported that data from a recent peer-reviewed clinical study involving Bentrio nasal spray's residence time and other rheological properties demonstrated superiority vs. a saline control.

Altamira Therapeutics Ltd. announced that data from three clinical studies with the Company's Bentrio nasal spray in allergic rhinitis will be presented February 25, at the Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI)

Altamira Therapeutics Ltd. provided an update on the clinical trials with Bentrio® in seasonal allergic rhinitis (SAR)

Verona Pharma plc (Nasdaq: VRNA) announces positive results of its Phase 3 ENHANCE-1 trial evaluating nebulized ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease (COPD).

优锐医药宣布与大昌华嘉（DKSH）医疗保健事业部达成合作，在中国香港、中国澳门上市发售BentrioTM鼻喷剂，标志着优锐医药在亚太区域的商业化权益实质性落地的首个里程碑。